BioLineRx is trading 6.38% down at $2.19 on October 7, 2026, consistent with broader biotech weakness and risk-off pressure rather than a confirmed company-specific catalyst. - No new company-specific announcement was identified for the session; its investor-relations release list shows the latest release was dated August 31. - Reuters reported markets were cautious amid higher Treasury yields and renewed Middle East supply concerns; oil prices rose ahead of the Federal Reserve minutes.